Enlivex (ENLV) Short-term Investments (2014 - 2025)
Enlivex (ENLV) posted quarterly Short-term Investments of $3.9 million for Q4 2025, down 80.88% year-over-year from $20.2 million in Q4 2024, and up 116.59% quarter-over-quarter from -$23.3 million in Q3 2025.
Enlivex (ENLV) Short-term Investments (2014 - 2025) Analysis & Trends
Enlivex's Short-term Investments history runs 12 years deep, the most recent figure standing at $3.9 million for Q4 2025.
- In Q4 2025, Short-term Investments fell 80.88% year-over-year to $3.9 million; the TTM figure through Dec 2025 stood at $3.9 million (down 80.88% YoY), while the FY2025 annual figure was $3.9 million, up 111.93% from the prior year.
- Short-term Investments for Q4 2025 stood at $3.9 million, up from -$23.3 million in the prior quarter.
- The five-year high for Short-term Investments was $62.9 million in Q4 2021, with the low at -$34.2 million in Q2 2023.
- The 5-year median for Short-term Investments is $14.0 million (2022), against an average of $7.0 million.
- Peak annual rise in Short-term Investments reached 8965.22% in 2023, while the deepest fall reached 401.7% in 2023.
- Enlivex's Short-term Investments stood at $62.9 million in 2021, then plunged by 100.48% to -$299000.0 in 2022, then jumped by 8965.22% to $26.5 million in 2023, then dropped by 23.81% to $20.2 million in 2024, then slumped by 80.88% to $3.9 million in 2025.
- Business Quant data shows ENLV's Short-term Investments at $3.9 million in Q4 2025, -$23.3 million in Q3 2025, and $17.6 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.86 Mn |
| Sep 30, 2025 | -23.27 Mn |
| Jun 30, 2025 | 17.62 Mn |
| Mar 31, 2025 | 18.50 Mn |
| Dec 31, 2024 | 20.20 Mn |
| Sep 30, 2024 | -31.22 Mn |
| Jun 30, 2024 | 22.20 Mn |
| Mar 31, 2024 | 21.52 Mn |
| Dec 31, 2023 | 26.51 Mn |
| Sep 30, 2023 | -30.24 Mn |
| Jun 30, 2023 | -34.22 Mn |
| Mar 31, 2023 | -31.18 Mn |
| Dec 31, 2022 | -299,000.00 |
| Jun 30, 2022 | 42.33 Mn |
| Mar 31, 2022 | 10.34 Mn |
| Dec 31, 2021 | 62.92 Mn |
| Jun 30, 2021 | 10.02 Mn |
| Mar 31, 2021 | 20.03 Mn |
| Dec 31, 2020 | 30.03 Mn |
| Sep 30, 2020 | 24.03 Mn |